Baker Bros. Advisors LP Ngm Biopharmaceuticals Inc Transaction History

Baker Bros. Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$10.58 - $17.5 $2.5 Million - $4.14 Million	-236,507 Reduced 81.05%	55,294 $709,000
Q1 2021 May 17, 2021	BUY	$24.99 - $31.93 $4.63 Million - $5.91 Million	185,185 Added 173.69%	291,801 $8.48 Million
Q4 2020 Feb 16, 2021	SELL	$16.21 - $31.44 $186,155 - $361,056	-11,484 Reduced 9.72%	106,616 $3.23 Million
Q3 2020 Nov 16, 2020	SELL	$15.59 - $19.97 $98,217 - $125,811	-6,300 Reduced 5.06%	118,100 $1.88 Million
Q2 2020 Aug 14, 2020	SELL	$11.97 - $23.47 $1.5 Million - $2.95 Million	-125,600 Reduced 50.24%	124,400 $2.46 Million
Q2 2019 Aug 14, 2019	BUY	$12.56 - $16.6 $3.14 Million - $4.15 Million	250,000 New	250,000 $3.66 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Baker Bros. Advisors LP with notifications on news.